A study in the Proceedings of the National Academy of Sciences found that inflammatory T-cell responses to hybrid insulin peptides in people who were genetically at-risk for type 1 diabetes were associated with poorer blood glucose measurements and higher risk of developing type 1 diabetes. "Patients with these specific immune responses may benefit from immune intervention to delay [type 1 diabetes] onset and possibly prevent it for years," said researcher Dr. Aaron Michels.